US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Actuate Therapeutics Inc

8.65

+0.04000.46%

Post-market: 8.650.00000.00%16:04 EDT

Volume:26.21K

Turnover:229.16K

Market Cap:169.71M

PE:-4.40

High:9.01

Open:8.63

Low:8.60

Close:8.61

Loading ...

Overview Company News Filings

Actuate Therapeutics Inc: to Report Topline Data From Phase 2 Trial of Elraglusib in 1H 2025

THOMSON REUTERS

Actuate Therapeutics Receives Ema Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

BRIEF-Actuate Therapeutics Announces Interim Phase 2 Data Of Elraglusib

Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer

Actuate Therapeutics Reports Phase 2 Trial Success for Elraglusib in Metastatic Pancreatic Cancer

MT Newswires Live

Actuate Therapeutics announces interim Phase 2 data of elraglusib

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Inc - Statistical Significance Met on Primary Endpoints in Phase 2 Trial

THOMSON REUTERS

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Inc - Elraglusib in Combination With Gnp Shows Favorable Risk-Benefit Profile

THOMSON REUTERS

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACTU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":8.65,"timestamp":1749844800000,"preClose":8.61,"halted":0,"volume":26207,"hourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.65,"latestTime":"16:04 EDT","volume":61,"amount":527.65,"timestamp":1749845056195},"delay":0,"floatShares":6049455,"shares":19619660,"eps":-1.967312,"marketStatus":"Market Closed","change":0.04,"latestTime":"06-13 16:00:00 EDT","open":8.63,"high":9.005,"low":8.6,"amount":229161.9001,"amplitude":0.047038,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.967312,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":8.61,"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.65,"latestTime":"16:04 EDT","volume":61,"amount":527.65,"timestamp":1749845056195},"volumeRatio":0.7680022060040623},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":6049455,"roa":"-413.43%","roe":"--","lyrEps":-3.258828,"volumeRatio":0.7680022060040623,"shares":19619660,"dividePrice":0,"high":9.005,"amplitude":0.047038,"preClose":8.61,"low":8.6,"week52Low":5.51,"pbRate":"-33.36","week52High":11.99,"institutionHeld":0,"latestPrice":8.65,"eps":-1.967312,"divideRate":0,"volume":26207,"delay":0,"ttmEps":-1.967312,"open":8.63,"prevYearClose":7.96,"prevWeekClose":8.96,"prevMonthClose":11.9,"prevQuarterClose":6.77,"fiveDayClose":8.96,"twentyDayClose":9.76,"sixtyDayClose":7.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501205703","title":"Actuate Therapeutics Inc: to Report Topline Data From Phase 2 Trial of Elraglusib in 1H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501205703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501205703?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA3HLZYK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2501057802","title":"Actuate Therapeutics Receives Ema Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501057802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501057802?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA3HLZYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2501068022","title":"Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501068022","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501068022?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, Jan.  07, 2025  (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on develop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005368/0/en/Actuate-Therapeutics-Receives-EMA-Orphan-Medicinal-Product-Designation-for-Elraglusib-for-the-Treatment-of-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4156","ACTU","LENZ"],"gpt_icon":0},{"id":"2492950256","title":"BRIEF-Actuate Therapeutics Announces Interim Phase 2 Data Of Elraglusib","url":"https://stock-news.laohu8.com/highlight/detail?id=2492950256","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492950256?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:05","pubTimestamp":1734444317,"startTime":"0","endTime":"0","summary":"Dec 17  - Actuate Therapeutics Inc   :   * ACTUATE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 2 DATA OF ELRAGLUSIB IN FIRST LINE TREATMENT OF METASTATIC PANCREATIC CANCER   * ACTUATE THERAPEUTICS INC - ELRAGLUSIB IN COMBINATION WITH GNP SHOWS FAVORABLE RISK-BENEFIT PROFILE   * ACTUATE THERAPEUTICS INC - TRIAL MET PRIMARY SAFETY ENDPOINT, FAVORABLE RISK-BENEFIT PROFILESource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","ACTU"],"gpt_icon":0},{"id":"2492957754","title":"Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492957754","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492957754?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:52","pubTimestamp":1734443520,"startTime":"0","endTime":"0","summary":"Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal cancer.The stock was up 12% to $9.73 in pre-market trading.The clinical-stage biopharmaceutical company said that the trial has shown that the combination of the treatments statistically increases in one-year the survival rate and median overall survival when compared to taking gemcitabine/nab-paclitaxel alone.Pancreatic ductal adenocarcinoma is the common type of this lethal disease, with an average five-year survival rate of less than 10%, according to the National Institutes of Health.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139","LENZ"],"gpt_icon":0},{"id":"2492439957","title":"Actuate Therapeutics Reports Phase 2 Trial Success for Elraglusib in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492439957","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492439957?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:46","pubTimestamp":1734443195,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics  said Tuesday that its phase 2 trial of elraglusib with gemcitabine/nab-paclitaxel, or GnP, in metastatic pancreatic cancer met primary endpoints of one-year survival rate.The study demonstrated a one-year survival rate of 43.6% in the elraglusib-GnP arm compared to 22.5% in the GnP control arm. Median overall survival was 9.3 months for the elraglusib combination versus 7.2 months for GnP alone, Actuate said.Actuate said it plans to share topline data and discuss next steps, including a phase 3 registration trial, with the US Food and Drug Administration in H1 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","ACTU"],"gpt_icon":0},{"id":"2492595789","title":"Actuate Therapeutics announces interim Phase 2 data of elraglusib","url":"https://stock-news.laohu8.com/highlight/detail?id=2492595789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492595789?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:35","pubTimestamp":1734442550,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-interim-phase-2-data-of-elraglusib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-interim-phase-2-data-of-elraglusib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ACTU"],"gpt_icon":0},{"id":"2492521399","title":"Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492521399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492521399?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:28","pubTimestamp":1734442097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA6WXZTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2492295213","title":"Actuate Therapeutics Inc - Statistical Significance Met on Primary Endpoints in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492295213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492295213?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:28","pubTimestamp":1734442097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA6WXZTM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2492954802","title":"Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954802?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUAVT686:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2492954385","title":"Actuate Therapeutics Inc - Elraglusib in Combination With Gnp Shows Favorable Risk-Benefit Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954385","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954385?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUAVT686:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2492954671","title":"Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954671","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954671?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":"Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in Med","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998209/0/en/Actuate-Therapeutics-Announces-Positive-Interim-Phase-2-Data-of-Elraglusib-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","PR","BK4213","ACTU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":52,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"ACTU","fiscalQuarterEnding":"2025/03","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1745380800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2025-06-12","current":-6.721745,"percent":0.140187,"low":-9.225925,"twenty":-6.383338,"median":-5.691423,"eighty":-5.08284,"high":-3.930949,"avg":-5.839716,"sd":0.896106,"marketCap":170102452},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-12","current":-6.721745,"twenty":-6.383338,"median":-5.691423,"eighty":-5.08284,"marketCap":170102452}],"updateTime":1749881878800}}}